Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study

被引:0
作者
Yusuke Tomita
Elizabeth A. Hibler
Yasuki Suruga
Joji Ishida
Kentaro Fujii
Kaishi Satomi
Koichi Ichimura
Nobuyuki Hirotsune
Isao Date
Yoshihiro Tanaka
Yoshihiro Otani
机构
[1] Hiroshima City Hiroshima Citizens Hospital,Department of Neurosurgery and Neuroendovascular Surgery
[2] Okayama University Faculty of Medicine,Department of Neurological Surgery
[3] Dentistry and Pharmaceutical Sciences,Division of Epidemiology, Department of Preventive Medicine
[4] Northwestern University Feinberg School of Medicine,Department of Pathology
[5] Kyorin University School of Medicine,Department of Brain Diseases Translational Research
[6] Graduate School of Medicine,Department of Preventive Medicine
[7] Juntendo University,Center for Arrhythmia Research
[8] Northwestern University Feinberg School of Medicine,undefined
[9] Northwestern University Feinberg School of Medicine,undefined
来源
Clinical and Experimental Medicine | 2023年 / 23卷
关键词
Pilocytic astrocytoma; Age-adjusted mortality; Age-adjusted incidence; SEER; USA;
D O I
暂无
中图分类号
学科分类号
摘要
Background Pilocytic astrocytomas (PAs) are central nervous system tumors with variable prognosis and poorly understood risk factors. Little evidence exists regarding the effect of age on mortality in PA. Therefore, we conducted a thorough characterization of PA in the US. Methods We queried the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2018 to extract age-adjusted incidence rate (AAIR), age-adjusted mortality rate (AAMR), and survival data on PA. The age group comparisons for each measure varied depending on available SEER data. We compared trends in AAIR and AAMR by two age groups (children, 0–19 years; adults, 20 + years) and by sex. The cumulative incidence function and the Fine-Gray competing risk model were applied by 0–19, 20–39, 40–59, and 60 + years of age groups. Results This study included 5211 incident PA and 462 PA-specific deaths between 2000 and 2018. Trends in AAIRs and AAMRs were almost constant between 2000 and 2018. Average AAIRs had a sharp peak in 1–4 years of age groups, whereas AAMRs had a gradual peak in 80–84 years of age groups. Age groups, tumor location, and race/ethnicity were significantly associated with PA-specific death, whereas only age was associated with other cause of deaths. Conclusions Trends in AAIRs and AAMRs were constant regardless of age. PAs in older populations, especially over 60 years old, have higher incidence of death than those in younger populations.
引用
收藏
页码:2301 / 2309
页数:8
相关论文
共 100 条
[1]  
Louis DN(2021)The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol 23 1231-1251
[2]  
Perry A(2020)CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017 Neuro Oncol 22 iv1-iv96
[3]  
Wesseling P(2018)DNA methylation-based classification of central nervous system tumours Nature 555 469-474
[4]  
Ostrom QT(2011)BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults Neuropathol Appl Neurobiol 37 803-806
[5]  
Patil N(2018)Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations Acta Neuropathol 136 273-291
[6]  
Cioffi G(2021)The age of adult pilocytic astrocytoma cells Oncogene 40 2830-2841
[7]  
Waite K(2019)Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States SEER-based analysis J Neurol Sci 400 148-152
[8]  
Kruchko C(2020)Has stage migration in renal cancer run its course? A SEER database analysis Clin Genitourin Cancer 18 e368-e373
[9]  
Barnholtz-Sloan JS(2019)Cancer mortality rates among US and foreign-born individuals: United States 2005–2014 Prev Med 126 vdab137-225
[10]  
Capper D(2021)Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors Neurooncol Adv 3 215-1461